compani lly- pm et intra-day price
invest summari qualiti sale ep beat maintain
ow rate pt expect upward earn revis move
share higher driven sale growth margin expans
takeaway support posit thesi revenu grew driven
volum growth partial off-set decreas due lower realiz
price decreas due unfavor impact fx growth
olumi basaglar emgal cyramza contribut percentag point
revenu growth repres total revenu notabl pipelin
event includ baqsimi approv new indic cyramza
emgal posit data readout verzenio trulic base
assess total subcutan sc tanezumab data initi
discuss fda ow pursu
regulatori submiss tanezumab patient oa expect
file announc verzenio demonstr statist
signific improv os phase clinic trial evalu verzenio
combin fulvestr treatment women hr
advanc metastat breast cancer previous treat endocrin therapi
plan submit data regulatori author present detail
data upcom medic meet later year non-gaap
basi gross margin increas percent yoy gross margin
increas percentag point increas gross margin primarili
due favor fx intern inventori greater manufactur
effici partial off-set unfavor product mix impact lower
realiz price revenu
report adjust dilut ep factset
consensu higher estim increas ep
guidanc factset consensu
revis model result increas ep
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
greater-than-expect brand and/or gener competit lilli key drugs/product
number lilli top-sel human pharmaceut product recent lost
lose next sever year signific patent protect and/or data protect
well key countri outsid certain signific product longer
effect exclus patent protect data protect non-biolog product
loss exclus whether expir consequ litig typic result
entri one gener competitor lead rapid sever declin
revenu especi histor outsid market penetr gener
follow loss exclus rapid pervas howev gener
market penetr increas mani market outsid includ japan europ
mani countri emerg market biolog humalog humulin erbitux
cyramza trulic taltz loss exclus may may result near-term entri
competitor version biosimilar due develop timelin manufactur challeng
and/or uncertainti regulatori pathway approv competitor version
setback lilli pipelin could headwind compani futur growth prospect
lilli compet larg number multi-national pharmaceut compani biotechnolog
compani gener pharmaceut compani compet success lilli must
continu deliv market innov cost-effect product meet import medic
lilli human pharmaceut busi subject increas govern price control
public privat restrict price reimburs access drug
could materi advers effect busi public privat payer take
increasingli aggress step control expenditur human pharmaceut
place restrict price reimburs patient access lilli medic
pressur could neg affect futur revenu net incom lilli expect
price reimburs access pressur govern privat payer insid
outsid becom sever
manufactur difficulti disrupt could lead product suppli problem
anim health manufactur complex highli regul
manufactur difficulti lilli facil contract facil failur refus
contract manufactur suppli contract quantiti could result product shortag
lead lost revenu difficulti disrupt could result qualiti regulatori
complianc problem natur disast mechan inform technolog system failur
inabl obtain sole-sourc raw intermedi materi addit given difficulti
predict sale new product long lead time necessari expans
regulatori qualif pharmaceut manufactur capac possibl lilli
could difficulti meet unanticip demand new product
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal trulic jardianc taltz verzenio key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal trulic jardianc taltz verzenio key drug line expectationspipelin advanc line expectationsno scenario casesal trulic jardianc taltz verzenio key drug expectationspipelin advanc expectationsno scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot volum increas key growth product trulic taltz jardianc verzenio basaglar emgal olumi favor effect fx rate intern inventori sold greater manufactur effici gross oper non oper pre-tax net discret tax benefit resolut certain global incom tax audit time impact tax reform tax adjust net averag adjust dilut cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom abemaciclib phase hr trial ramucirumab merestinib data pivot phase trial biliari tract ramucirumab us/japan regulatori submiss phase relay data egfr nsclc erlotinib ramucirumab regulatori action high afp hepatocellular cancer eu/japan august exclus europ japan septemb nordisk oral semaglutidefda decis treatment adult type agonist initi phase studi agonist initi phase studi non-alcohol steatohepat ret inhibitor registr phase data nsclc thyroid cancer late dulaglutid complet safeti data trial higher dose trulic late dulaglutid regulatori submiss higher dose trulic end ret inhibitor submiss nsclc thyroid cancer end agonist initi surpass studi type combin type diabet present result trial medic oral phase full data top-line on-going ad phase initi crohn pegyl phase renal cell posit alloster modul pam phase readout parkinson diseas nasal glucagon regulatori decis eu top-line data congest heart failur chf exercis abil ixekizumab regulatori submiss radiograph axial spondyloarthr ixekizumab regulatori action radiograph axial ixekizumab regulatori submiss non-radiograph axial ixekizumab phase top-line data psoriasi head-to-head vs tremfya guselkumab ramucirumab detail phase relay data egfr nsclc readout medic studi public scientif meet data releas psoriat outcom studybegin enrol empagliflozin approv type approv acut rapid lisprou regulatori submiss type type abemaciclib monarch os studi medic meet premetrex patent litig rule altern salt form appeal dulaglutid regulatori submiss altern dose type pegyl data top-lin disclosur pancreat cancersourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom studi overcom avail baselin phase emperial-preserv outcom trial chronic phase emperial-reduc outcom trial chronic abemaciclib keytrudaphas data hr breast cancer kra nsclc non-squam nsclcend ceclor vancocin eddingpharm chinad nordisk oral semaglutidefda decis cv risk reduct adult type diabet regulatori submiss mg sc moderate-to-sever posit alloster modul readout symptom lewi bodi pegyl folfoxphas sequoia pancreat cancer top-line baricitinib phase top-line data alopecia insulin-fcphas data once-weekli basal data moderate-to-sever atop rapid lispropotenti top-line data agonist initi surpass cvot event driven power cv dulaglutid label updat rewind pegyl pembrolizumab cypress nsclc top-line pegyl nivolumab io nave cypress nsclc top-line phase emperor hf-reduc outcom trial chronic phase emperor hf-preserv outcom trial chronic phase empa-kidney outcom trial chronic kidney insulin deliveri systemphas readout alzheim diseas readout dian antibodyphas readout identifi exploratori biomark key kinas inhibitorphas btk inhibitor primari complet phase trial cll/sll readout solid tumorsearli readout cancer pain studi abemaciclib result phase adjuv studi hr breast cancer baricitinib phase top-line data system lupu anti-tau antibodi phase readout alzheim top-line data ulcer agonist phase surpass data type diabet vs glargin establish pegyl insulin deliveri systempotenti outcom studymain studi premetrex eu loss premetrex japan loss control bayer submissionl agonist complet phase surpass program type diabetesmay premetrex patent expir loss pediatr exclus empagliflozin phase estimate primari complet date chronic kidney diseas control bayer potenti agonist potenti global studi overcom end data abemaciclib nce exclus readout aspirinu patent dulaglutid patent agonist data surpass cvot event driven power cv patent patent jentaduet patent ramucirumab patent ixekizumab patent abemaciclib patent baricitinib eu patent baricitinib patent ixekizumab eu loss baricitinib japan patent galcanezumab patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
million compound-annual-growth-rate year end decemb oper expens oper net dilut changetot oper expens incom nmnmnmnmnmnmnmnmnmnmnmoper net dilut cantor fitzgerald research compani report exclud amort intang primarili associ cost market product acquir licens third parti cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat busi develop activ co ltd inc hydra bioscienc charg primarili associ sever cost incur result action taken reduc compani cost structur well expens associ separ elanco anim health busi adjust tax reform tax expens associ separ elanco anim health busi non-gaap earn loss per share continu oper amount present assum split-off elanco occur begin period present therefor exclud share accept lilli exchang offer exclud amort intang primarili associ cost market product acquir licens third parti exclud cost associ up-front payment acquir in-process research develop project acquir transact busi combin relat busi develop activ ac immun sa immunext inc exclud charg primarili associ acceler vest loxo oncolog employe equiti award part close acquisit loxo oncolog non-gaap earn per share assum disposit elanco occur begin period present therefor includ benefit reduct share common stock outstand exclud charg relat suspens promot lartruvo exclud discontinu oper busi exclud amort intang primarili associ cost market product acquir licens third parti exclud cost associ up-front payment acquir in-process research develop project acquir transact busi combin cost relat busi develop activ avid bioscienc inc exhibit margin analysi
cantor fitzgerald research compani report exhibit quarterli sale analysi
million year end decemb product pipelin product changeu product cantor fitzgerald research compani report cardio includ zalutia livalo endocrinolog includ acto humapen neuro includ amyvid symbyax onco includ gemzar portrazza pharma includ ceclor keflex licens fee incom jardianc revenu includ glyxambi synjardi trajenta revenu includ jentadueto biolog humalog humulin erbitux cyramza trulic taltz loss exclus may may result near-term entri competitor version biosimilar due develop timelin manufactur challeng and/or uncertaintiesin regulatori pathway approv competitor version exhibit annual sale analysi
pharmaceut product pharmaceut intern pharmaceut launch pipeline/newli launch product cantor fitzgerald research compani report cardio includ zalutia livalo endocrinolog includ acto humapen neuro includ amyvid symbyax onco includ gemzar portrazza pharma includ ceclor keflex licens fee incom jardianc revenu includ glyxambi synjardi trajenta revenu includ jentadueto biolog humalog humulin erbitux cyramza trulic taltz loss exclus may may result near-term entri competitor version biosimilar due develop timelin manufactur challeng and/or uncertaintiesin regulatori pathway approv competitor version year end decemb exhibit analysi
million year end decemb flow provid oper activ net depreci net chang work net cash provid oper flow invest activitiespurchas net proce sale acquisit net cash acquired- net cash use invest flow financ activ repay issuanc long term dividend net cash use provid financ effect exchange-r cash net decreas increas cash equival begin equival end sourc cantor fitzgerald research compani report exhibit balanc sheet analysi
million year end decemb account receiv less allow doubt current total current plant properti total total liabil sharehold equityaccount payabl accru total current long term debt total sharehold total stockhold non-controlling total liabil stockhold sourc cantor fitzgerald research compani report juli
engag discoveri develop manufactur sale pharmaceut product compani sell product world-wide
follow therapeut area neurosci endocrinolog oncolog cardiovascular
